Complementary serum proteomic analysis of autoimmune hepatitis in mice and patients

Journal of Translational Medicine

Shufang Liang¹  Fengming Gong¹  Yuling Liu¹  Wen Ma¹  Yongkang Wu²  Xinyu Zhao¹  Guoshun Li¹  Hongbin Li¹ 

[1] State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, P. R. China

关键词: Isobaric tags for relative and absolute quantification (iTRAQ);    Serum proteomics;    Autoimmune hepatitis;   

Others  :  827413
DOI  :  10.1186/1479-5876-11-146

 received in 2013-02-01, accepted in 2013-06-04,  发布年份 2013

【 摘 要 】

Background

Autoimmune hepatitis (AIH) is a chronic liver disease caused by inflammation of the liver. The etiology of AIH remains elusive, and there are no reliable serum biomarkers.

Methods

In order to identify candidate biomarkers, 2-DE analysis of serum proteins was performed using a mouse model of AIH induced by treatment with concanavalin A (ConA). To enrich samples for low abundance molecules a commercial albumin removal reagent was used. In an independent analysis, candidate biomarkers were identified in AIH patient’s serum by a targeted iTRAQ (isobaric tags for relative and absolute quantification) identification. Candidates were validated in independent cohorts of ConA treated mice and AIH patients by ELISA (enzyme-linked immuno sorbent assay).

Results

Nine proteins were differentially expressed in AIH mice treated with con-A. Two of these, the third component of complement (C3) and alpha-2-macroglobulin (A2M) were also up-regulated in AIH patient’s sera by a targeted iTRAQ identification. In separate validation studies, serum C3 and A2M levels were increased in mice with ConA treatment after 20-40 h and in 34 AIH patients in a subgroup analysis, females with AIH aged 20–50 years old displayed the largest increases in serum A2M level. Biological network analysis implements the complement cascade and protease inhibitors in the pathogenesis of AIH.

Conclusion

The serum proteins C3 and A2M are increased both in a mouse model and in patients with AIH by both 2-DE and iTRAQ methods. This integrated serum proteomics investigation should be applicable for translational researchers to study other medical conditions.

【 授权许可】

   
2013 Li et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 8.

Figure 8.

Figure 6.

Figure 8.

Figure 8.

【 参考文献 】

• [1]Krawitt EL: Autoimmune hepatitis. N Engl J Med 2006, 354:54-66.
• [2]Chung H, Watanabe T, Kudo M, Maenishi O, Wakatsuki Y, Chiba T: Identification and characterization of IgG4‒associated autoimmune hepatitis. Liver Int 2010, 30:222-231.
• [3]Xia Q, Lu F, Yan HP, Wang HX, Feng X, Zhao Y, Liu BY, Wang J, Li P, Xue Y: Autoantibody profiling of Chinese patients with autoimmune hepatitis using immunoproteomic analysis. J Proteome Res 2008, 7:1963-1970.
• [4]Lohse AW, Mieli-Vergani G: Autoimmune hepatitis. J Hepatol 2011, 55:171-182.
• [5]Vierling JM: Diagnosis and treatment of autoimmune hepatitis. Curr Gastroenterol Rep 2012, 14:25-36.
• [6]Song Q, Liu G, Hu S, Zhang Y, Tao Y, Han Y, Zeng H, Huang W, Li F, Chen P: Novel autoimmune hepatitis-specific autoantigens identified using protein microarray technology. J Proteome Res 2009, 9:30-39.
• [7]Ballot E, Bruneel A, Labas V, Johanet C: Identification of rat targets of anti-soluble liver antigen autoantibodies by serologic proteome analysis. Clin Chem 2003, 49:634-643.
• [8]Huguet S, Labas V, Duclos‒Vallee JC, Bruneel A, Vinh J, Samuel D, Johanet C, Ballot E: Heterogeneous nuclear ribonucleoprotein A2/B1 identified as an autoantigen in autoimmune hepatitis by proteome analysis. Proteomics 2004, 4:1341-1345.
• [9]Lu F, Xia Q, Ma Y, Yuan G, Yan H, Qian L, Hu M, Wang M, Lu H, Wang H: Serum proteomic-based analysis for the identification of a potential serological marker for autoimmune hepatitis. Biochem Bioph Res Co 2008, 367:284-290.
• [10]Tahiri F, Le Naour F, Huguet S, Lai‒Kuen R, Samuel D, Johanet C, Saubamea B, Tricottet V, Duclos‒Vallee JC, Ballot E: Identification of plasma membrane autoantigens in autoimmune hepatitis type 1 using a proteomics tool. Hepatology 2008, 47:937-948.
• [11]Zingaretti C, Cardaci A, Moro M, Crosti M, Sinisi A, Sugliano E, Cheroni C, Marabita F, Nogarotto R, Bonnal RJP: Identification of new autoantigens by protein array indicates a role for IL4 neutralization in autoimmune hepatitis. Mol Cell Proteomics 2012, 11:1885-1897.
• [12]Obermayer-Straub P, Strassburg CP, Manns MP: Autoimmune hepatitis. J Hepatol 2000, 32:181-197.
• [13]Ciocca DR, Calderwood SK: Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperon 2005, 10:86-103.
• [14]Liang S, Shen G: Biomarkers of glioma. In Molecular Targets of CNS Tumors. Edited by Garami M. InTech Press; 2011:325-342. Available from: http://www.intechopen.com/articles/show/title/biomarkers-of-glioma webciteISBN 978-953-307-736-9
• [15]Anderson NL, Anderson NG: The human plasma proteome history, character, and diagnostic prospects. Mol Cell Proteomics 2002, 1:845-867.
• [16]Christen U, Holdener M, Hintermann E: Animal models for autoimmune hepatitis. Autoimmun Rev 2007, 6:306-311.
• [17]Wang HX, Liu M, Weng SY, Li JJ, Xie C, He HL, Guan W, Yuan YS, Gao J: Immune mechanisms of concanavalin A model of autoimmune hepatitis. World J Gastroenterol 2012, 18:119-125.
• [18]Gong F, Liang S, He C, Shen G, Xu Y: The optimized conditions of two dimensional polyacrylamide gel electrophoresis for serum proteomics. J Proteomics Bioinform 2008, 1:250-257.
• [19]Tarr AW, Urbanowicz RA, Ball JK: The role of humoral innate immunity in hepatitis C virus infection. Viruses 2012, 4:1-27.
• [20]Schiødt FV, Ostapowicz G, Murray N, Satyanarana R, Zaman A, Munoz S, Lee WM: Alpha‒fetoprotein and prognosis in acute liver failure. Liver Transplant 2006, 12:1776-1781.
• [21]Liu FC, Chang DM, Lai JH, Lin CK, Chen HC, Hou TY, Kuo SY: Autoimmune hepatitis with raised alpha-fetoprotein level as the presenting symptoms of systemic lupus erythematosus: a case report. Rheumatol Int 2007, 27:489-491.
• [22]Aparicio JL, Peña C, Retegui LA: Autoimmune hepatitis-like disease in C57BL/6 mice infected with mouse hepatitis virus A59. Int Immunopharmacol 2011, 11:1591-1598.
• [23]Hardtke-Wolenski M, Taubert R, Jaeckel E: Animal models of autoimmune liver disease–What is relevant for immune-mediated liver disease? Dig Dis 2012, 14(1):2-10.
• [24]Molina H, Perkins SJ, Guthridge J, Gorka J, Kinoshita T, Holers VM: Characterization of a complement receptor 2 (CR2, CD21) ligand binding site for C3. An initial model of ligand interaction with two linked short consensus repeat modules. J Immunol 1995, 154:5426-5435.
• [25]Shariat-Madar Z, Schmaier AH: Review: the plasma kallikrein/kinin and renin angiotensin systems in blood pressure regulation in sepsis. J Endotoxin Res 2004, 10:3-13.
• [26]Stegbauer J, Lee DH, Seubert S, Ellrichmann G, Manzel A, Kvakan H, Muller DN, Gaupp S, Rump LC, Gold R: Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system. Proc Natl Acad Sci USA 2009, 106:14942-14947.
• [27]Liang S, Xu Z, Xu X, Zhao X, Huang C, Wei Y: Quantitative proteomics for cancer biomarker discovery. Comb Chem High T Scr 2012, 15:221-231.
• [28]Tunstall A, Merriman J, Milne I, James K: Normal and pathological serum levels of alpha2-macroglobulins in men and mice. J Clin Pathol 1975, 28:133-139.
• [29]Chen M, Daha MR, Kallenberg CGM: The complement system in systemic autoimmune disease. J Autoimmun 2010, 34:J276-J286.
• [30]Flierl MA, Gaudiani JL, Sabel AL, Long CS, Stahel PF, Mehler PS: Complement C3 serum levels in anorexia nervosa: a potential biomarker for the severity of disease? Ann Gen Psychiatry 2011, 10:10-16. BioMed Central Full Text
• [31]Hussain N, Jaffery G, Hasnain S: Serum complement C3 and C4 levels in relation to diagnosis of lupus nephritis. Trop J Pharm Res 2008, 7:1117-1121.
• [32]James K, Merriman J, Gray R, Duncan L, Herd R: Serum alpha 2-macroglobulin levels in diabetes. J Clin Pathol 1980, 33:163-166.
• [33]Gao X, Liu H, Ding G, Wang Z, Fu H, Ni Z, Ma J, Liu F, Fu Z: Complement C3 deficiency prevent against the onset of streptozotocin-induced autoimmune diabetes involving expansion of regulatory T cells. Clin Immunol 2011, 104:236-243.
• [34]Laarman AJ, Ruyken M, Malone CL, Van Strijp JAG, Horswill AR, Rooijakkers SHM: Staphylococcus aureus metalloprotease aureolysin cleaves complement C3 to mediate immune evasion. J Immunol 2011, 186:6445-6453.
• [35]Tu Z, Li Q, Chou HS, Hsieh CC, Meyerson H, Peters MG, Bu H, Fung JJ, Qian S, Lu L: Complement mediated hepatocytes injury in a model of autoantibody induced hepatitis. Immunobiology 2011, 216:528-534.
• [36]White IR, Patel K, Symonds WT, Dev A, Griffin P, Tsokanas N, Skehel M, Liu C, Zekry A, Cutler P: Serum proteomic analysis focused on fibrosis in patients with hepatitis C virus infection. J Transl Med 2007, 5:33-41. BioMed Central Full Text
• [37]Vasudev NS, Ferguson RE, Cairns DA, Stanley AJ, Selby PJ, Banks RE: Serum biomarker discovery in renal cancer using 2‒DE and prefractionation by immunodepletion and isoelectric focusing; increasing coverage or more of the same? Proteomics 2008, 8:5074-5085.
• [38]Zhou J, Liang S, Fang L, Chen L, Tang M, Xu Y, Fu A, Yang J, Wei Y: Quantitative proteomic analysis of HepG2 cells treated with quercetin suggests IQGAP1 involved in quercetin-induced regulation of cell proliferation and migration. OMICS 2009, 13:93-103.
• [39]Liang S, Xu Y, Shen G, Liu Q, Zhao X, Xu Z, Xie X, Gong F, Li R, Wei Y: Quantitative protein expression profiling of 14‒3‒3 isoforms in human renal carcinoma shows 14‒3‒3 epsilon is involved in limitedly increasing renal cell proliferation. Electrophoresis 2009, 30:4152-4162.
• [40]Unwin RD, Griffiths JR, Whetton AD: Simultaneous analysis of relative protein expression levels across multiple samples using iTRAQ isobaric tags with 2D nano LC-MS/MS. Nat Protoc 2010, 5:1574-1582.
• [41]Chong PK, Lee H, Zhou J, Liu SC, Loh MCS, Wang TT, Chan SP, Smoot DT, Ashktorab H, So JBY: ITIH3 is a potential biomarker for early detection of gastric cancer. J Proteome Res 2010, 9:3671-3679.
• [42]Ogata Y, Charlesworth MC, Higgins LA, Keegan BM, Vernino S, Muddiman DC: Differential protein expression in male and female human lumbar cerebrospinal fluid using iTRAQ reagents after abundant protein depletion. Proteomics 2007, 7:3726-3734.